RPRX / Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likel more_horizontal

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial res more_horizontal

Royalty Pharma offers a unique exposure in the pharmaceutical sector thanks to a diversified portfolio and lower operational risk vs. competitors. The more_horizontal

Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnersh more_horizontal

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming inve more_horizontal

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Royalty Pharma acquires royalties on drugs in the commercial phase and the development phase. Thanks to a milestone payment, this year's cash receipts more_horizontal

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44t more_horizontal